Andy Tran

Andy Tran is a seasoned investment professional with extensive experience in the biotechnology and healthcare sectors. Currently serving as a Board Observer and Investor at ReCode Therapeutics, a Board Director and Lead Investor at Maze Therapeutics, and a Board Director and Lead Investor at GentiBio, Andy Tran also holds the position of Principal at Matrix Capital Management Company, L.P., focusing on long-term investments from an $8 billion assets under management hedge fund. Previously, as an Investment Partner at Andreessen Horowitz, Andy Tran specialized in early-stage ventures in biotech and engineering, leading investments in notable companies such as Scribe Therapeutics and insitro. Andy Tran's educational background includes an MBA from Harvard Business School and valedictorian honors from Michael E. DeBakey High School for Health Professions.